Er-xian decoction
Er-xian decoction has been studied in 3 papers since 2022: 1 trial in people, 1 in animals, 1 review; 1 in the past year. The newest paper, May 14, 2026: “Er-xian Decoction: A comprehensive review on chemical constituents, quality control, pharmacokinetics, pharmacological properties and clinical applications”.
See all 3 papers on er-xian decoction
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“serum anti-Mullerian hormone (AMH) level in DOR patients with EXD treatment was higher than that in DOR patients without EXD treatment”
- 1 lab in 1 country
- Human trial1
- Animals1
What did studies of er-xian decoction find?
3Studies of er-xian decoction measured 3 outcomes: osteoporosis, menopausal syndrome and anti-Müllerian hormone.
Osteoporosis
downin humans1
1 study
Osteoporosis
downin humans1
Er-xian decoction decreases osteoporosis in osteoporosis.
“improve symptoms in patients with menopausal syndrome, osteoporosis, and premature ovarian failure, based on randomized trials involving thousands of patients”
Reviewin osteoporosis
Phytomedicine : international journal of phytotherapy and phytopharmacology
Menopausal syndrome
downin humans1
1 study
Menopausal syndrome
downin humans1
Er-xian decoction decreases menopausal syndrome in menopausal syndrome.
“improve symptoms in patients with menopausal syndrome, osteoporosis, and premature ovarian failure, based on randomized trials involving thousands of patients”
Reviewin menopausal syndrome
Phytomedicine : international journal of phytotherapy and phytopharmacology
Anti-Müllerian hormone
upin humans1
1 study
Anti-Müllerian hormone
upin humans1
Er-xian decoction increases anti-Müllerian hormone in DOR patients.
“serum anti-Mullerian hormone (AMH) level in DOR patients with EXD treatment was higher than that in DOR patients without EXD treatment”
Human trialin DOR patients
Chemical biology & drug design